Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

Correction: Photobiomodulation: lasers vs. light emitting diodes?

Vladimir Heiskanen a and Michael R. Hamblin *bcd
aOral and Maxillofacial Diseases, University of Helsinki, Finland
bWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
cDepartment of Dermatology, Harvard Medical School, Boston, MA 02115, USA
dHarvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA. E-mail: hamblin@helix.mgh.harvard.edu

Received 22nd October 2018 , Accepted 22nd October 2018

First published on 31st October 2018


Correction for ‘Photobiomodulation: lasers vs. light emitting diodes?’ by Vladimir Heiskanen and Michael R. Hamblin, Photochem. Photobiol. Sci., 2018, 17, 1003–1017.


The Conflicts of Interest statement should be corrected to include a list of potential conflicts.

 

Dr Hamblin is on the following Scientific Advisory Boards: Transdermal Cap Inc, Cleveland, OH; BeWell Global Inc, Wan Chai, Hong Kong; Hologenix Inc. Santa Monica, CA; LumiThera Inc, Poulsbo, WA; Vielight, Toronto, Canada; Bright Photomedicine, Sao Paulo, Brazil; Quantum Dynamics LLC, Cambridge, MA; Global Photon Inc, Bee Cave, TX; Medical Coherence, Boston MA; NeuroThera, Newark DE; JOOVV Inc, Minneapolis-St Paul MN; Illumiheal & Petthera, Shoreline, WA; MB Lasertherapy, Houston, TX.

 

Dr Hamblin has been a consultant for USHIO Corp, Japan; Merck KGaA, Darmstadt, Germany; Philips Electronics Nederland B.V.; Johnson & Johnson Inc, Philadelphia, PA; AIRx Medical, Pleasanton CA; FIR Industries, Inc. Ramsey, NJ; UVLRx Therapeutics, Oldsmar, FL; Ultralux UV Inc, Lansing MI; Photothera Inc, Carlsbad, CA.

 

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.


This journal is © The Royal Society of Chemistry and Owner Societies 2019